Clene share price logo

Clene

NASDAQ: CLNN

$3.74

-0.18

(-4.59%)

as on

Clene Stock Performance

as on November 17, 2026 at 7:59 am IST

  • Day's Low

    Day's High

    $3.51
    $3.84
    downward going graph

    6.15%

    Downside

    2.67%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $3.02
    $10.84
    downward going graph

    19.38%

    Downside

    189.84%

    Upside

    downward going graph

Clene share price movements today

Previous Close
$3.92
Open
$3.82
Volume
653.1K
Market Cap
$56.4M
Day's Low - High
$3.51 - $3.84
52 Week Low - High
$3.02 - $10.84

Clene Historical Returns

1 Month Return
+ 26.45 %
3 Month Return
-5.31 %
1 Year Return
-53.99 %
3 Year Return
-57.38 %
5 Year Return
-96.13 %

Clene Stock Fundamentals & Key Indicators

Check Clene market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$56.4M

EPS (TTM)

-2.4

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.61%

PE Ratio (TTM)

-1.63

Industry PE ratio

15.84

PEG Ratio

-0.09

EBITDA

-26.1M

Revenue (TTM)

238.0K

Profit Margin

-80.67%

Return On Equity TTM

175.40%

Clene vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Clene with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$56.4M-96.13%-1.63-80.67%0.00%
NA$19.0BNA15.557.10%3.07%
Neutral$29.7B-32.21%-8.6033.53%6.37%
Neutral$18.4B-45.75%-20.8033.61%7.11%

Stock Returns calculator for Clene Stock including INR - Dollar returns

The Clene stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Clene investment value today

Current value as on today

₹46,515

Returns

-₹53,485

(-53.49%)

Returns from Clene Stock

-₹56,103 (-56.1%)

Dollar Impact

₹2,618 (+2.62%)

Analyst Recommendation on Clene Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Clene. Average target price of $32.2

Clene Share Price Target

Get share price movements and forecasts by analysts on Clene.

What analysts predicted

88.39%UPSIDE

Target Price

$32.2

Current Price

$3.74

Analyzed by

2 Analysts

High

$31

Target

$32.20

Low

$30

Clene target price $32.2, a slight upside of 88.39% compared to current price of $3.74. According to 2 analysts rating.

Indian Investors' Interest in Clene Stock

Search interest for Clene Stock has increased by 37% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:37% versus previous 30 day period

Clene Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-7
-7
-8
-4
-5
-5
-7
-2
-5
-6
EBITDA
-5
-6
-12
0
-6
-7
-8
-6
-4
-5
Interest Expense
1
1
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-6
-7
-13
0
-7
-8
-9
-8
-13
3
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-6
-7
-13
0
-7
-8
-9
-8
-13
3
Net Profit Margin
80.22%
79.31%
80.22%
75.31%
100.00%
100.00%
70.13%
-2266.67%
60.00%
71.43%

Clene Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
0
0
0
0
0
0
Gross Profit
-
0
0
0
0
0
0
0
Operating Income
0
-16
-20
-49
-48
-40
-33
-23
EBITDA
-8
-15
-16
-8
-25
-43
-33
-21
Interest Expense
-
0
0
0
3
4
4
2
Depreciation
0
0
0
0
1
1
1
1
Income Before Tax
0
-16
-18
-10
-29
-49
-39
-26
Income Tax Expense
-
-
0
0
-
-
-
-
Net Income
0
-16
-19
-9
-29
-49
-39
-26
Net Profit Margin
0.00%
0.00%
68.45%
60.03%
94.50%
81.50%
79.53%
78.50%

Clene Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-6
-7
-13
0
-7
-8
-9
-8
-13
3
Operating Cash Flow
-6
-3
-4
-5
-4
-3
-4
-4
-2
-4
Investing Cash Flow
6
0
0
-
-
0
0
-
0
0
Financing Cash Flow
0
-4
2
2
2
4
2
5
6
4
Change in Cash
0
-7
-2
-2
-2
0
-2
0
3
0

Clene Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
0
-16
-19
-9
-29
-49
-39
-26
Operating Cash Flow
0
-13
-18
-34
-39
-30
-21
-18
Investing Cash Flow
-46
0
0
-1
-10
-1
6
0
Financing Cash Flow
46
5
69
27
17
42
-1
11
Change in Cash
0
-7
50
-8
-31
10
-16
-6

Global Institutional Holdings in Clene

Check out the Institutions with significant holdings in Clene.

Funds
Holdings
Jonathon Gay
16.17%
David Matlin
6.39%
Alison Mosca
4.89%
REED N WILCOX
3.99%
VANGUARD INDEX FUNDS
2.30%

Clene News & Key Events

  • img

    Today's Timeline - 04 November

    Wed, 07:00 PM

    -

    Clene reports Q3 2026 net income of $3.9 million, submits NDA for CNM-Au8 in ALS treatment.

Insights on Clene

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -13.42M → 3.91M (in $), with an average increase of 442.9% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, CLNN stock has moved up by 26.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, The Kraft Heinz Company has given 1.0% return, outperforming this stock by 55.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Clene Inc. Common Stock has experienced a drawdown of -57.4%, however Associated British Foods Plc American Depositary Shares resisted the overall trend and outperformed by 31.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 90.0K → 56.0K (in $), with an average decrease of 37.8% per quarter

About Clene

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
OrganisationClene
Headquarters6550 South Millrock Drive, Salt Lake City, UT, 84121, US
IndustryBiotechnology
CEORobert Etherington

Key Management of Clene

Name

Title

Mr. Robert Etherington MBA

CEO, President & Director

Mr. Morgan R. Brown CPA, M.B.A.

Chief Financial Officer

Mr. Mark G. Mortenson ESQ.

Chief Science Officer

Mr. Jerry Miraglia J.D.

General Counsel & Corporate Secretary

Ms. Mary Anne Mcneil

Head of Human Resources

Mr. Michael T. Hotchkin

Chief Development Officer

Dr. Benjamin M. Greenberg M.D., M.H.S.

Head of Medical

FAQs

What is Clene share price today?

Clene share price today is $3.74 as on at the close of the market. Clene share today touched a day high of $3.84 and a low of $3.51.

What is the 52 week high and 52 week low for Clene share?

Clene share touched a 52 week high of $10.84 on and a 52 week low of $3.02 on . Clene stock price today i.e. is closed at $3.74,which is 65.50% down from its 52 week high and 24.04% up from its 52 week low.

What is Clene's market capitalisation today?

Clene market capitalisation is $0.00T as on .

How to invest in Clene Stock (CLNN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Clene on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Clene Stock (CLNN) from India?

Indian investors can start investing in Clene (CLNN) shares with as little as ₹93.92250061035156 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹939.23 in Clene stock (as per the Rupee-Dollar exchange rate as on ). Based on Clene share’s latest price of $3.74 as on November 17, 2026 at 2:29 am IST, you will get 2.6738 shares of Clene. Learn more about fractional shares .

What are the returns that Clene has given to Indian investors in the last 5 years?

Clene stock has given -96.13% share price returns and 26.58% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?